Identification of resveratrol oligomers as inhibitors of cystic fibrosis transmembrane conductance regulator by high-throughput screening of natural products from Chinese medicinal plants

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Zhang, Yaofang ^a   Yu, Bo ^a   Sui, Yujie ^b   Gao, Xin ^c   Yang, Hong ^a   Ma, Tonghui ^b  

^a LIAONING NORMAL UNIVERSITY   (China)

^b DALIAN MEDICAL UNIVERSITY   (China)

^c YANBIAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 EPSILON VINIFERIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; RESVERATROL; TRANS EPSILON VINIFERIN; UNCLASSIFIED DRUG; BIOLOGICAL PRODUCT; HERBACEOUS AGENT; STILBENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHINESE MEDICINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG ISOLATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; GRAPEVINE; HIGH THROUGHPUT SCREENING; IC 50; INTESTINE FLUID; MEDICINAL PLANT; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; VITIS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; FRACTIONATION; HUMAN; IC50; INTESTINE MUCOSA; MALE; METABOLISM; MOUSE;

ANIMALS; BIOLOGICAL PRODUCTS; CHEMICAL FRACTIONATION; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUGS, CHINESE HERBAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INHIBITORY CONCENTRATION 50; INTESTINAL MUCOSA; MALE; MICE; MOLECULAR STRUCTURE; PLANTS, MEDICINAL; RATS; STILBENES;

EID: 84899423417     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094302     Document Type: Article

References (41)

1. Frizzell RA, Hanrahan JW (2012) Physiology of epithelial chloride and fluid secretion. Cold Spring Harb Perspect Med 2: a009563.
2. Barrett KE, Keely SJ (2000) Chloride secretion by the intestinal epithelium: Molecular basis and regulatory aspects. Annu Rev Physiol 62: 535-572. (Pubitemid 30618274)
3. Jakab RL, Collaco AM, Ameen NA (2011) Physiological relevance of cell-specific distribution patterns of CFTR, NKCC1, NBCe1, and NHE3 along the crypt-villus axis in the intestine. Am J Physiol Gastrointest Liver Physiol 300: G82-98.
4. Venkatasubramanian J, Ao M, Rao MC (2010) Ion transport in the small intestine. Curr Opin Gastroenterol 26: 123-128.
5. Greger R (2000) Role of CFTR in the colon. Annu Rev Physiol 62: 467-491.
6. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, et al. (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245: 1066-1073. (Pubitemid 19231814)
7. Kunzelmann K (1999) The cystic fibrosis transmembrane conductance regulator and its function in epithelial transport. Rev Physiol Biochem Pharmacol 137: 1-70.
8. Chao AC, de Sauvage FJ, Dong YJ, Wagner JA, Goeddel DV, et al. (1994) Activation of intestinal CFTR Cl2 channel by heat-stable enterotoxin and guanylin via cAMP-dependent protein kinase. EMBO J 13: 1065-1072. (Pubitemid 24074713)
9. Gabriel SE, Brigman KN, Koller BH, Boucher RC, Stutts MJ (1994) Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model. Science 266: 107-109. (Pubitemid 24345328)
10. Ma T, Thiagarajah JR, Yang H, Sonawane ND, Folli C, et al. (2002) Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. J Clin Invest 110: 1651-1658. (Pubitemid 35424243)
11. Li H, Sheppard DN (2009) Therapeutic potential of cystic fibrosis transmembrane conductance regulator (CFTR) inhibitors in polycystic kidney disease. BioDrugs 23: 203-216.
12. Riordan JR (2008) CFTR function and prospects for therapy. Annu Rev Biochem 77: 701-726.
13. Muanprasat C, Sonawane ND, Salinas D, Taddei A, Galietta LJ, et al. (2004) Discovery of glycine hydrazide pore-occluding CFTR inhibitors: mechanism, structure-activity analysis, and in vivo efficacy. J Gen Physiol 124: 125-137. (Pubitemid 39038187)
14. Verkman AS, Synder D, Tradtrantip L, Thiagarajah JR, Anderson MO (2013) CFTR inhibitors. Curr Pharm Des 19: 3529-3541.
15. Galietta LV, Jayaraman S, Verkman AS (2001) Cell-based assay for high-throughput quantitative screening of CFTR chloride transport agonists. Am J Physiol Cell Physiol 281: C1734-1742.
16. Zegarra-Moran O, Romio L, Folli C, Caci E, Becq F, et al. (2002) Correction of G551D-CFTR transport defect in epithelial monolayers by genistein but not by CPX or MPB-07. Br J Pharmacol 137: 504-512. (Pubitemid 35221904)
17. He C, Zhang H, Su Z, Zhou J, Yang H, et al. (2004) Synthesis and characterization of a small molecule thiazolidinone CFTR chloride channel inhibitor. Chem Res Chinese U 20: 334-337.
18. Yang H, Shelat AA, Guy RK, Gopinath VS, Ma T, et al. (2003) Nanomolar Affinity Small Molecule Correctors of Defective {Delta}F508-CFTR Chloride Channel Gating. J Biol Chem 278: 35079-35085. (Pubitemid 37102270)
19. Ma T, Vetrivel L, Yang H, Pedemonte N, Zegarra-Moran O, et al. (2002) High-affinity activators of cystic fibrosis transmembrane conductance regulator (CFTR) chloride conductance identified by high-throughput screening. J Biol Chem 277: 37235-37241.
20. Kopeikin Z, Sohma Y, Li M, Hwang TC (2010) On the mechanism of CFTR inhibition by a thiazolidinone derivative. J Gen Physiol 136: 659-671.
21. - channel. Trends Pharmacol 20: 448-453.
22. Sheppard DN, Welsh MJ (1999) Structure and function of the CFTR chloride channel. Physiol Rev 79: S23-45. (Pubitemid 29058908)
23. Cragg GM, Newman DJ (2013) Natural products: a continuing source of novel drug leads. Biochim Biophys Acta 1830: 3670-3695.
24. Luzhetskyy A, Pelzer S, Bechthold A (2007) The future of natural products as a source of new antibiotics. Curr Opin Investig Drugs 8: 608-613. (Pubitemid 47205245)
25. Li JW, Vederas JC (2009) Drug discovery and natural products: end of an era or an endless frontier? Science 325: 161-165.
26. Zghonda N, Yoshida S, Araki M, Kusunoki M, Mliki A, et al. (2011) Greater effectiveness of e-viniferin in red wine than its monomer resveratrol for inhibiting vascular smooth muscle cell proliferation and migration. Biosci Biotechnol Biochem 75: 1259-1267.
27. Vitrac X, Bornet A, Vanderlinde R, Valls J, Richard T, et al. (2005) Determination of stilbenes (delta -viniferin, trans-astringin, trans-piceid, cis- and trans-resveratrol, epsilon -viniferin) in Brazilian wines. J Agric Food Chem 53: 5664-5669. (Pubitemid 41022461)
28. Landrault N, Larronde F, Delaunay JC, Castagnino C, Vercauteren J, et al. (2002) Levels of stilbene oligomers and astilbin in French varietal wines and in grapes during noble rot development. J Agric Food Chem 50: 2046-2052. (Pubitemid 34260009)
29. Frombaum M, Le Clanche S, Bonnefont-Rousselot D, Borderie D (2012) Antioxidant effects of resveratrol and other stilbene derivatives on oxidative stress and *NO bioavailability: Potential benefits to cardiovascular diseases. Biochimie 94: 269-276.
30. Catalgol B, Batirel S, Taga Y, Ozer NK (2012) Resveratrol: French paradox revisited. Front Pharmacol 3: 141.
31. González-Sarrías A, Gromek S, Niesen D, Seeram NP, Henry GE (2011) Resveratrol oligomers isolated from Carex species inhibit growth of human colon tumorigenic cells mediated by cell cycle arrest. J Agric Food Chem 59: 8632-8638.
32. Kim JY, Jeong HY, Lee HK, Kim S, Hwang BY, et al. (2012) Neuroprotection of the leaf and stem of Vitis amurensis and their active compounds against ischemic brain damage in rats and excitotoxicity in cultured neurons. Phytomedicine 19: 150-159.
33. - conductance in human sweat ducts. Exp Physiol 89: 417-425.
34. Privat C, Telo JP, Bernardes-Genisson V, Vieira A, Souchard JP, et al. (2002) Antioxidant properties of trans-epsilon-viniferin as compared to stilbene derivatives in aqueous and nonaqueous media. J Agric Food Chem 50: 1213-1217. (Pubitemid 34194082)
35. Bavaresco L, Fregoni C, Cantù E, Trevisan M (1999) Stilbene compounds: from the grapevine to wine. Drugs Exp Clin Res 25: 57-63. (Pubitemid 29257596)
36. Kapetanovic IM, Muzzio M, Huang Z, Thompson TN, McCormick DL (2011) Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother Pharmacol 68: 593-601.
37. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK (2011) High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32: 1377-1382.
38. Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, et al. (2010) Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 70: 9003-9011.
39. la Porte C, Voduc N, Zhang G, Seguin I, Tardiff D, et al. (2010) Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin Pharmacokinet 49: 449-454.
40. Yang S, Yu B, Sui Y, Zhang Y, Wang X, et al. (2013) CFTR chloride channel is a molecular target of the natural cancer preventive agent resveratrol. Pharmazie 68: 772-776.
41. Zhang S, Blount AC, McNicholas CM, Skinner DF, Chestnut M, et al. (2013) Resveratrol enhances airway surface liquid depth in sinonasal epithelium by increasing cystic fibrosis transmembrane conductance regulator open probability. PLoS One 8:e81589.